Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human parkinson's disease

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Gollamudi, Seema ^a   Johri, Ashu ^a   Calingasan, Noel Y ^a   Yang, Lichuan ^a   Elemento, Olivier ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA CATENIN; EPHRIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; MANEB; MESSENGER RNA; PARAQUAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PESTICIDE; PYRIDABEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; PYRIDAZINE DERIVATIVE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; IMMUNOREACTIVITY; MACROPHAGE; MALE; MESENCEPHALON; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PROTEIN AGGREGATION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DNA MICROARRAY; DRUG EFFECT; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; CORPUS STRIATUM; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MALE; MANEB; MESENCEPHALON; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAQUAT; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PESTICIDES; PYRIDAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84860489734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036191     Document Type: Article

References (67)

1. Braak H, Braak E, (2000) Pathoanatomy of Parkinson's disease. J Neurol 247 (Suppl 2): II3-10.
2. Tremblay L, (2010) [Pathophysiology of Parkinson's disease: an update]. Bull Acad Natl Med 194: 1321-1331; discussion 1331-1322.
3. Goetz CG, (2011) The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 1: a008862.
4. Bezard E, Przedborski S, (2011) A tale on animal models of Parkinson's disease. Mov Disord 26: 993-1002.
5. Cannon JR, Greenamyre JT, (2010) Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 184: 17-33.
6. Beal MF, (2010) Parkinson's disease: a model dilemma. Nature 466: S8-10.
7. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, et al. (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100: 1469-1479.
8. Navarro A, Bandez MJ, Gomez C, Repetto MG, Boveris A, (2010) Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity. J Bioenerg Biomembr 42: 405-412.
9. Banerjee R, Starkov AA, Beal MF, Thomas B, (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792: 651-663.
10. Zhang J, Fitsanakis VA, Gu G, Jing D, Ao M, et al. (2003) Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84: 336-346.
11. Thrash B, Uthayathas S, Karuppagounder SS, Suppiramaniam V, Dhanasekaran M, (2007) Paraquat and maneb induced neurotoxicity. Proc West Pharmacol Soc 50: 31-42.
12. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, et al. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277: 1641-1644.
13. Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK, (2005) Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 113: 1263-1270.
14. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, et al. (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7: 1-11.
15. Vogt IR, Lees AJ, Evert BO, Klockgether T, Bonin M, et al. (2006) Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol 199: 465-478.
16. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, et al. (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21: 305-313.
17. Zhang Y, James M, Middleton FA, Davis RL, (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137B: 5-16.
18. Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, et al. (2009) A Cross-Study Transcriptional Analysis of Parkinson's Disease. PLoS ONE 4: e4955.
19. Edwards YJK, Beecham GW, Scott WK, Khuri S, Bademci G, et al. (2011) Identifying Consensus Disease Pathways in Parkinson's Disease Using an Integrative Systems Biology Approach. PLoS ONE 6: e16917.
20. Patel S, Singh K, Singh S, Singh MP, (2008) Gene expression profiles of mouse striatum in control and maneb+paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol Biotechnol 40: 59-68.
21. Yin L, Lu L, Prasad K, Richfield EK, Unger EL, et al. (2011) Genetic-based, differential susceptibility to paraquat neurotoxicity in mice. Neurotoxicol Teratol 33: 415-421.
22. Surmeier DJ, Guzman JN, Sanchez-Padilla J, (2010) Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 47: 175-182.
23. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, et al. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447: 1081-1086.
24. Morgan AR, Turic D, Jehu L, Hamilton G, Hollingworth P, et al. (2007) Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 144B: 762-770.
25. Si W, Aluisio L, Okamura N, Clark SD, Fraser I, et al. (2010) Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem 115: 475-482.
26. Chang SC, Magee AI, (2009) Acyltransferases for secreted signalling proteins (Review). Mol Membr Biol 26: 104-113.
27. Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, et al. (2011) Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 44: 38-52.
28. Deng Q, Andersson E, Hedlund E, Alekseenko Z, Coppola E, et al. (2011) Specific and integrated roles of Lmx1a, Lmx1b and Phox2a in ventral midbrain development. Development 138: 3399-3408.
29. Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, et al. (2007) The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. Eur J Neurosci 26: 417-423.
30. Vogler M, (2012) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19: 67-74.
31. White JH, (2010) Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. J Steroid Biochem Mol Biol 121: 234-238.
32. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 105: 10907-10912.
33. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, et al. (2010) Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 116: 843-851.
34. Hurley MJ, Dexter DT, (2012) Voltage-gated calcium channels and Parkinson's disease. Pharmacol Ther.
35. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, et al. (2011) Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee. PLoS Genet 7: e1002237.
36. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, et al. (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74: 980-989.
37. Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, et al. (2007) A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3: e98.
38. Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, et al. (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 25: 309-327.
39. Riess O, Thies U, Siedlaczck I, Potisek S, Graham R, et al. (1994) Precise mapping of the brain alpha 2-adrenergic receptor gene within chromosome 4p16. Genomics 19: 298-302.
40. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA, (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 873: 225-234.
41. Austin PJ, Betts MJ, Broadstock M, O'Neill MJ, Mitchell SN, et al. (2010) Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol 160: 1741-1753.
42. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, et al. (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2: 52ra73.
43. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, et al. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144: 689-702.
44. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408.
45. Lin J, Handschin C, Spiegelman BM, (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370.
46. Ali F, Ali NS, Bauer A, Boyle JJ, Hamdulay SS, et al. (2010) PPARdelta and PGC1alpha act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. Cardiovasc Res 85: 701-710.
47. Grochot-Przeczek A, Dulak J, Jozkowicz A, (2012) Haem oxygenase-1: non-canonical roles in physiology and pathology. Clin Sci (Lond) 122: 93-103.
48. Chien WL, Lee TR, Hung SY, Kang KH, Lee MJ, et al. (2011) Impairment of oxidative stress-induced heme oxygenase-1 expression by the defect of Parkinson-related gene of PINK1. J Neurochem 117: 643-653.
49. McMahon M, Lamont DJ, Beattie KA, Hayes JD, (2010) Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 107: 18838-18843.
50. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP, (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103: 15091-15096.
51. Bueler H, (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 218: 235-246.
52. Xiong H, Wang D, Chen L, Choo YS, Ma H, et al. (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119: 650-660.
53. Parfitt DA, Michael GJ, Vermeulen EG, Prodromou NV, Webb TR, et al. (2009) The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1. Hum Mol Genet 18: 1556-1565.
54. Anderson JF, Siller E, Barral JM, (2011) The neurodegenerative-disease-related protein sacsin is a molecular chaperone. J Mol Biol 411: 870-880.
55. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D, (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
56. Witt SN, (2010) Hsp70 molecular chaperones and Parkinson's disease. Biopolymers 93: 218-228.
57. Cleren C, Calingasan NY, Chen J, Beal MF, (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 94: 995-1004.
58. Blakely BD, Bye CR, Fernando CV, Horne MK, Macheda ML, et al. (2011) Wnt5a regulates midbrain dopaminergic axon growth and guidance. PLoS ONE 6: e18373.
59. Inestrosa NC, Arenas E, (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11: 77-86.
60. Parish CL, Castelo-Branco G, Rawal N, Tonnesen J, Sorensen AT, et al. (2008) Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 118: 149-160.
61. Rawal N, Corti O, Sacchetti P, Ardilla-Osorio H, Sehat B, et al. (2009) Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun 388: 473-478.
62. Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, et al. (1998) Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. Neuroreport 9: 1379-1383.
63. Wexler EM, Rosen E, Lu D, Osborn GE, Martin E, et al. (2011) Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci Signal 4: ra65.
64. Lenzken SC, Romeo V, Zolezzi F, Cordero F, Lamorte G, et al. (2011) Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration. Hum Mutat 32: 168-182.
65. Inzelberg R, Jankovic J, (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69: 1542-1550.
66. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
67. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B, (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628.